Trade Names:Romazicon- Injection 0.1 mg/mLAnexate (Canada)
Antagonizes actions of benzodiazepines on CNS by blocking receptors.
Mean C max is 24 ng/mL (range, 11 to 43 ng/mL); mean AUC was 15 ng•h/mL (range, 10 to 22 ng•h/mL).
Initial distribution t 1/ 2 is 7 to 15 min. VD initial is 0.5 L/kg; Vd ss is 0.l77 to 1.60 L/kg. Protein binding is about 50%.
Primarily hepatically metabolized and dependent on hepatic blood flow (highly extracted).
Terminal t 1/ 2 is 41 to 79 min. Total Cl is 0.7 to 1.3 L/h/kg (increases by 50% during ingestion of food). Less than 1% is excreted unchanged in the urine; 90% to 95% is excreted in urine and 5% to 10% in feces.
1 to 2 min.
6 to 10 min.
Related to the plasma concentration of the benzodiazepine as well as the dose of flumazenil.
Mean total Cl decreased 40% to 60%; t 1/ 2 increases to 1.3 h.Severe
Mean total Cl decreased 75%; t 1/ 2 increases to 2.4 h.Children1 to 17 yr of age
The t 1/ 2 is shorter and more variable, ranging 20 to 75 min.
Complete or partial reversal of sedative effects of benzodiazepines where general anesthesia induced or maintained with benzodiazepines, where sedation produced with benzodiazepines for diagnostic or therapeutic procedures, and for the management of benzodiazepine overdose.
Hypersensitivity to flumazenil or benzodiazepines; in patients given benzodiazepines for control of a potentially life-threatening condition (eg, status epilepticus); in patients showing signs of serious cyclic antidepressant overdose.
IV 0.2 mg over 15 sec. If desired level of consciousness is not achieved in 45 sec, additional 0.2 mg doses can be administered at 60 sec intervals (max, 1 mg). In event of resedation, repeat doses (0.2 mg/min to max 1 mg) at 20 min intervals as needed (max, 3 mg/h).Management of Suspected Benzodiazepine OverdoseAdults
IV 0.2 mg over 30 sec. If desired level of consciousness is not achieved in 30 sec, an additional dose of 0.3 mg over 30 sec can be administered. Further doses of 0.5 mg over 30 sec can be administered at 1 min intervals as needed (max, 3 mg).
Toxic effects of other drugs taken in toxic doses may emerge with reversal of benzodiazepine effect.
None well documented.
Cutaneous vasodilation (eg, sweating, flushing, hot flushes); palpitations.
Convulsions; headache; dizziness; agitation; emotional lability; fatigue; paresthesia; insomnia; dyspnea; hypoesthesia.
Visual field defect; diplopia; blurred vision.
Injection-site pain; injection-site reaction; dry mouth.
Category C .Labor and delivery
Not recommended; effects on newborn are unknown.
Safety and efficacy not determined.
Elimination of flumazenil is reduced in patients with liver disease.
The effects of flumazenil may wear off before a long-acting benzodiazepine is completely cleared from the body.
Flumazenil may cause benzodiazepine withdrawal symptoms in individuals who have been taking benzodiazepines long enough to have some degree of tolerance or physical dependence.
Use with caution in patients with alcoholism and other drug dependencies because of the increased frequency of benzodiazepine tolerance and dependence observed in these patient populations.
Use with caution in patients with head injury because of risk of precipitating convulsions or altering cerebral blood flow in patients receiving benzodiazepines.
Use of flumazenil to diagnose benzodiazepine-induced sedation in the ICU is not recommended because of the risk of adverse reactions.
Do not use flumazenil until effects of neuromuscular blocking agents have been fully reversed.
Flumazenil is intended as an adjunct to, not a substitute for, proper management of overdose patients (eg, airway maintenance, decontamination).
Flumazenil may provoke panic attacks in patients with a history of panic disorder.
Flumazenil may not fully reverse postoperative airway problems or ventilatory insufficiency induced by benzodiazepines; its effects may wear off before the effects of many benzodiazepines.
Reversal of benzodiazepine effects may be associated with the onset of seizures in certain high-risk populations including the following: Concurrent major sedative-hypnotic drug withdrawal; recent therapy with repeated doses of parenteral benzodiazepines; myoclonic jerking or seizure activity prior to flumazenil in overdose cases; concurrent cyclic antidepressant poisoning.
Copyright © 2009 Wolters Kluwer Health.